

# Ophthalmic Drugs Market Size, Share & Trends Analysis Report By Drug Class (Steroidal drugs, Anti-VEGF Agents), By Disease, By Dosage Form, By Route of Administration, By Product Type, By Drug Type, By Region, And Segment Forecasts, 2025 - 2030

<https://marketpublishers.com/r/O5F00C3269BEN.html>

Date: February 2025

Pages: 150

Price: US\$ 5,950.00 (Single User License)

ID: O5F00C3269BEN

## Abstracts

This report can be delivered to the clients within Immediate

### Ophthalmic Drugs Market Growth & Trends

The global ophthalmic drugs market size is expected to reach USD 62.08 billion by 2030, garnering a CAGR of 8.5% from 2025 to 2030, according to a new report by Grand View Research, Inc. The rising awareness about ophthalmic disorders and the surge in demand for ophthalmic drugs are the factors propelling the market growth.

Moreover, an increase in the prevalence of eye diseases such as age-related macular degeneration, cataract, dry eye, diabetic retinopathy, glaucoma, and others are anticipated to boost the demand for ophthalmic drugs.

According to BrightFocus Foundation in 2021, it is estimated that over 3 million Americans are living with glaucoma, and, among them over 2.7 million patients were affected by the most common type of glaucoma i.e. open-angle glaucoma. Moreover, 3.3 million people are affected by blindness and low vision in the U.S. Some of the major risk factors for glaucoma and blindness are, higher age, family history, thin cornea, and high eye pressure. This creates a wide population base for ophthalmic drugs, thereby, ensuring lucrative growth.

Furthermore, ocular therapeutic and drug delivery companies are receiving funding to expedite R&D for advancements in technologies to develop novel drugs, which is likely to fuel market growth. For instance, in June 2020, Re-Vana Therapeutics received USD 3.25 million in pre-series A funding from Qubis, ExSight Ventures, LLC, Clarendon Fund Managers, Visionary Ventures, and Techstart Ventures LLP. The

funding is expected to boost the development of Re-Vana Therapeutics' EyeLief & OcuLief biodegradable technologies that can be used for a small molecule as well as biologics delivery.

Moreover, the rising geriatric population is the key driver for the ophthalmic drugs market growth. According to Safe Eyes America, the most common risk factors for ophthalmic diseases are high age, family history, diabetes, and high blood pressure. For instance, as per AMERICA'S HEALTH RANKINGS senior report 2021 it was estimated that more than 54 million adults of age more than 65 live in the U.S., and that population accounted for 16.5% of the total population. According to Macular Degeneration Research AMD is the leading reason for blindness in U.S. people over the age of 60. Ongoing regulatory approvals for ophthalmic products are likely to support market growth. For instance, in June 2022 Santen Pharmaceutical Co., Ltd announced that it has got marketing and manufacturing approval for the dry eye disease treatment DIQUAS LX ophthalmic solution in Japan. This solution is the improved formulation that has reduced dosing frequency and improved patient compliance.

#### Ophthalmic Drugs Market Report Highlights

Anti-VEGF agents segment held the largest share in 2024 owing to their rising demand and lesser adverse effects

Retinal disorders held the largest market share in 2024 owing to the rising prevalence of age-related macular degeneration and diabetic retinopathy

The topical route of administration dominated the market in 2024 owing to factors such as the benefits of the topical route as it delivers the drug to the targeted site and ease of use

The eye drops segment is expected to hold the largest share in 2024 owing to rising demand for eye drops, high patient compliance, and availability of OTC products

Asia Pacific is expected to exhibit the fastest growth over the forecast period due to advancements in healthcare infrastructure, increasing demand for eye products, and a large patient pool

## Contents

### CHAPTER 1. METHODOLOGY AND SCOPE

- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
  - 1.2.1. Drug class
  - 1.2.2. Disease
  - 1.2.3. Route of administration
  - 1.2.4. Dosage type
  - 1.2.5. Product type
  - 1.2.6. Drug type
  - 1.2.7. Regional scope
  - 1.2.8. Estimates and forecasts timeline.
- 1.3. Research Methodology
- 1.4. Information Procurement
  - 1.4.1. Purchased database
  - 1.4.2. GVR's internal database
  - 1.4.3. Secondary sources
  - 1.4.4. Primary research
  - 1.4.5. Details of primary research
- 1.5. Information or Data Analysis
  - 1.5.1. Data analysis models
- 1.6. Market Formulation & Validation
- 1.7. Model Details
  - 1.7.1. Commodity flow analysis (Model 1)
  - 1.7.2. Approach 1: Commodity flow approach
  - 1.7.3. Volume price analysis (Model 2)
  - 1.7.4. Approach 2: Volume price analysis
- 1.8. List of Secondary Sources
- 1.9. List of Primary Sources
- 1.10. Objectives

### CHAPTER 2. EXECUTIVE SUMMARY

- 2.1. Market Outlook
- 2.2. Segment Outlook
  - 2.2.1. Drug class outlook
  - 2.2.2. Disease outlook

- 2.2.3. Route of administration outlook
- 2.2.4. Dosage type outlook
- 2.2.5. Product type outlook
- 2.2.6. Drug type outlook
- 2.2.7. Regional outlook
- 2.3. Competitive Insights

## **CHAPTER 3. OPHTHALMIC DRUGS MARKET VARIABLES, TRENDS & SCOPE**

- 3.1. Market Lineage Outlook
  - 3.1.1. Parent market outlook
  - 3.1.2. Related/ancillary market outlook.
- 3.2. Market Dynamics
  - 3.2.1. Market driver analysis
    - 3.2.1.1. Increasing diseases prevalence
    - 3.2.1.2. String development pipeline
    - 3.2.1.3. Advancements in drug delivery
  - 3.2.2. Market restraint analysis
    - 3.2.2.1. Patent expiry of blockbuster drugs
- 3.3. Ophthalmic Drugs Market Analysis Tools
  - 3.3.1. Industry Analysis – Porter's
  - 3.3.2. PESTEL Analysis

## **CHAPTER 4. OPHTHALMIC DRUGS MARKET: DRUG CLASS ESTIMATES & TREND ANALYSIS**

- 4.1. Segment Dashboard
- 4.2. Ophthalmic Drugs Market: Drug Class Movement Analysis
- 4.3. Ophthalmic Drugs Market Size & Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
- 4.4. Anti-Allergy
  - 4.4.1. Anti-Allergy market revenue estimates and forecasts, 2018 - 2030 (USD Million)
- 4.5. Anti-VEGF agents
  - 4.5.1. Anti-VEGF agents market revenue estimates and forecasts, 2018 - 2030 (USD Million)
- 4.6. Anti-inflammatory
  - 4.6.1. Anti-inflammatory market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  - 4.6.2. Non-steroidal Drugs

4.6.2.1. Non-steroidal Drugs market revenue estimates and forecasts, 2018 - 2030 (USD Million)

4.6.3. Steroids

4.6.3.1. Steroids market revenue estimates and forecasts, 2018 - 2030 (USD Million)

4.7. Anti-glaucoma

4.7.1. Anti-glaucoma market revenue estimates and forecasts, 2018 - 2030 (USD Million)

4.8. Gene & Cell Therapy

4.8.1. Gene & Cell Therapy market revenue estimates and forecasts, 2018 - 2030 (USD Million)

4.9. Others

4.9.1. Others market revenue estimates and forecasts, 2018 - 2030 (USD Million)

## **CHAPTER 5. OPHTHALMIC DRUGS MARKET: DISEASE ESTIMATES & TREND ANALYSIS**

5.1. Segment Dashboard

5.2. Ophthalmic Drugs Market: Disease Movement Analysis

5.3. Ophthalmic Drugs Market Size & Trend Analysis, by Disease, 2018 to 2030 (USD Million)

5.4. Dry eye

5.4.1. Dry eye market revenue estimates and forecasts, 2018 - 2030 (USD Million)

5.4.1.1. Gels

5.4.1.1.1. Gels market revenue estimates and forecasts, 2018 - 2030 (USD Million)

5.4.1.2. Eye solutions & suspensions

5.4.1.2.1. Eye solutions & suspensions market revenue estimates and forecasts, 2018 - 2030 (USD Million)

5.4.1.3. Capsules & tablets

5.4.1.3.1. Capsules & tablets market revenue estimates and forecasts, 2018 - 2030 (USD Million)

5.4.1.4. Eye drops

5.4.1.4.1. Eye drops market revenue estimates and forecasts, 2018 - 2030 (USD Million)

5.4.1.5. Ointments

5.4.1.5.1. Ointments market revenue estimates and forecasts, 2018 - 2030 (USD Million)

5.5. Allergies

5.5.1. Allergies market revenue estimates and forecasts, 2018 - 2030 (USD Million)

5.5.1.1. Gels

- 5.5.1.1.1. Gels market revenue estimates and forecasts, 2018 - 2030 (USD Million)
- 5.5.1.2. Eye solutions & suspensions
  - 5.5.1.2.1. Eye solutions & suspensions market revenue estimates and forecasts, 2018 - 2030 (USD Million)
- 5.5.1.3. Capsules & tablets
  - 5.5.1.3.1. Capsules & tablets market revenue estimates and forecasts, 2018 - 2030 (USD Million)
- 5.5.1.4. Eye drops
  - 5.5.1.4.1. Eye drops market revenue estimates and forecasts, 2018 - 2030 (USD Million)
- 5.5.1.5. Ointments
  - 5.5.1.5.1. Ointments market revenue estimates and forecasts, 2018 - 2030 (USD Million)
- 5.6. Glaucoma
  - 5.6.1. Glaucoma market revenue estimates and forecasts, 2018 - 2030 (USD Million)
    - 5.6.1.1. Gels
      - 5.6.1.1.1. Gels market revenue estimates and forecasts, 2018 - 2030 (USD Million)
    - 5.6.1.2. Eye solutions & suspensions
      - 5.6.1.2.1. Eye solutions & suspensions market revenue estimates and forecasts, 2018 - 2030 (USD Million)
    - 5.6.1.3. Capsules & tablets
      - 5.6.1.3.1. Capsules & tablets market revenue estimates and forecasts, 2018 - 2030 (USD Million)
    - 5.6.1.4. Eye drops
      - 5.6.1.4.1. Eye drops market revenue estimates and forecasts, 2018 - 2030 (USD Million)
    - 5.6.1.5. Ointments
      - 5.6.1.5.1. Ointments market revenue estimates and forecasts, 2018 - 2030 (USD Million)
- 5.7. Infection
  - 5.7.1. Infection market revenue estimates and forecasts, 2018 - 2030 (USD Million)
    - 5.7.1.1. Gels
      - 5.7.1.1.1. Gels market revenue estimates and forecasts, 2018 - 2030 (USD Million)
    - 5.7.1.2. Eye solutions & suspensions
      - 5.7.1.2.1. Eye solutions & suspensions market revenue estimates and forecasts, 2018 - 2030 (USD Million)
    - 5.7.1.3. Capsules & tablets
      - 5.7.1.3.1. Capsules & tablets market revenue estimates and forecasts, 2018 - 2030 (USD Million)

#### 5.7.1.4. Eye drops

5.7.1.4.1. Eye drops market revenue estimates and forecasts, 2018 - 2030 (USD Million)

#### 5.7.1.5. Ointments

5.7.1.5.1. Ointments market revenue estimates and forecasts, 2018 - 2030 (USD Million)

### 5.8. Retinal Disorders

5.8.1. Retinal disorders market revenue estimates and forecasts, 2018 - 2030 (USD Million)

#### 5.8.2. By Dosage Type

##### 5.8.2.1. Gels

5.8.2.1.1. Gels market revenue estimates and forecasts, 2018 - 2030 (USD Million)

##### 5.8.2.2. Eye solutions & suspensions

5.8.2.2.1. Eye solutions & suspensions market revenue estimates and forecasts, 2018 - 2030 (USD Million)

##### 5.8.2.3. Capsules & tablets

5.8.2.3.1. Capsules & tablets market revenue estimates and forecasts, 2018 - 2030 (USD Million)

##### 5.8.2.4. Eye drops

5.8.2.4.1. Eye drops market revenue estimates and forecasts, 2018 - 2030 (USD Million)

##### 5.8.2.5. Ointments

5.8.2.5.1. Ointments market revenue estimates and forecasts, 2018 - 2030 (USD Million)

#### 5.8.3. By Type

##### 5.8.3.1. Macular degeneration

5.8.3.1.1. Macular degeneration market revenue estimates and forecasts, 2018 - 2030 (USD Million)

##### 5.8.3.2. Diabetic retinopathy

5.8.3.2.1. Diabetic retinopathy market revenue estimates and forecasts, 2018 - 2030 (USD Million)

##### 5.8.3.3. Others

5.8.3.3.1. Others market revenue estimates and forecasts, 2018 - 2030 (USD Million)

### 5.9. Uveitis

5.9.1. Uveitis market revenue estimates and forecasts, 2018 - 2030 (USD Million)

#### 5.9.1.1. Gels

5.9.1.1.1. Gels market revenue estimates and forecasts, 2018 - 2030 (USD Million)

#### 5.9.1.2. Eye solutions & suspensions



5.9.1.2.1. Eye solutions & suspensions market revenue estimates and forecasts, 2018 - 2030 (USD Million)

5.9.1.3. Capsules & tablets

5.9.1.3.1. Capsules & tablets market revenue estimates and forecasts, 2018 - 2030 (USD Million)

5.9.1.4. Eye drops

5.9.1.4.1. Eye drops market revenue estimates and forecasts, 2018 - 2030 (USD Million)

5.9.1.5. Ointments

5.9.1.5.1. Ointments market revenue estimates and forecasts, 2018 - 2030 (USD Million)

5.10. Others

5.10.1. Others market revenue estimates and forecasts, 2018 - 2030 (USD Million)

5.10.1.1. Gels

5.10.1.1.1. Gels market revenue estimates and forecasts, 2018 - 2030 (USD Million)

5.10.1.2. Eye solutions & suspensions

5.10.1.2.1. Eye solutions & suspensions market revenue estimates and forecasts, 2018 - 2030 (USD Million)

5.10.1.3. Capsules & tablets

5.10.1.3.1. Capsules & tablets market revenue estimates and forecasts, 2018 - 2030 (USD Million)

5.10.1.4. Eye drops

5.10.1.4.1. Eye drops market revenue estimates and forecasts, 2018 - 2030 (USD Million)

5.10.1.5. Ointments

5.10.1.5.1. Ointments market revenue estimates and forecasts, 2018 - 2030 (USD Million)

## **CHAPTER 6. OPHTHALMIC DRUGS MARKET: ROUTE OF ADMINISTRATION ESTIMATES & TREND ANALYSIS**

6.1. Segment Dashboard

6.2. Ophthalmic Drugs Market: Route of Administration Movement Analysis

6.3. Ophthalmic Drugs Market Size & Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)

6.4. Topical

6.4.1. Topical market revenue estimates and forecasts, 2018 - 2030 (USD Million)

6.5. Local Ocular

6.5.1. Local ocular market revenue estimates and forecasts, 2018 - 2030 (USD Million)



#### 6.5.1.1. Subconjunctival

6.5.1.1.1. Subconjunctival market revenue estimates and forecasts, 2018 - 2030  
(USD Million)

#### 6.5.1.2. Intravitreal

6.5.1.2.1. Intravitreal market revenue estimates and forecasts, 2018 - 2030 (USD  
Million)

#### 6.5.1.3. Retrobulbar

6.5.1.3.1. Retrobulbar market revenue estimates and forecasts, 2018 - 2030 (USD  
Million)

#### 6.5.1.4. Intracameral

6.5.1.4.1. Intracameral market revenue estimates and forecasts, 2018 - 2030 (USD  
Million)

### 6.6. Sytemic

6.6.1. Sytemic market revenue estimates and forecasts, 2018 - 2030 (USD Million)

## **CHAPTER 7. OPHTHALMIC DRUGS MARKET: DOSAGE TYPE ESTIMATES & TREND ANALYSIS**

### 7.1. Segment Dashboard

### 7.2. Ophthalmic Drugs Market: Dosage Type Movement Analysis

7.3. Ophthalmic Drugs Market Size & Trend Analysis, by Dosage Type, 2018 to 2030  
(USD Million)

### 7.4. Gels

7.4.1. Gels market revenue estimates and forecasts, 2018 - 2030 (USD Million)

### 7.5. Eye solutions & suspensions

7.5.1. Eye solutions & suspensions market revenue estimates and forecasts, 2018 -  
2030 (USD Million)

### 7.6. Capsules & Tablets

7.6.1. Capsules & tablets market revenue estimates and forecasts, 2018 - 2030 (USD  
Million)

### 7.7. Eye drops

7.7.1. Eye drops market revenue estimates and forecasts, 2018 - 2030 (USD Million)

### 7.8. Ointments

7.8.1. Ointments market revenue estimates and forecasts, 2018 - 2030 (USD Million)

## **CHAPTER 8. OPHTHALMIC DRUGS MARKET: PRODUCT TYPE ESTIMATES & TREND ANALYSIS**

### 8.1. Segment Dashboard

- 8.2. Ophthalmic Drugs Market: Product Type Movement Analysis
- 8.3. Ophthalmic Drugs Market Size & Trend Analysis, by Product Type, 2018 to 2030 (USD Million)
- 8.4. OTC
  - 8.4.1. OTC market revenue estimates and forecasts, 2018 - 2030 (USD Million)
- 8.5. Prescription Drugs
  - 8.5.1. Prescription drugs market revenue estimates and forecasts, 2018 - 2030 (USD Million)

## **CHAPTER 9. OPHTHALMIC DRUGS MARKET: DRUG TYPE ESTIMATES & TREND ANALYSIS**

- 9.1. Segment Dashboard
- 9.2. Ophthalmic Drugs Market: Drug Type Movement Analysis
- 9.3. Ophthalmic Drugs Market Size & Trend Analysis, by Drug Type, 2018 to 2030 (USD Million)
- 9.4. Branded Drugs
  - 9.4.1. Branded drugs market revenue estimates and forecasts, 2018 - 2030 (USD Million)
- 9.5. Generic Drugs
  - 9.5.1. Generic drugs market revenue estimates and forecasts, 2018 - 2030 (USD Million)

## **CHAPTER 10. OPHTHALMIC DRUGS MARKET: REGIONAL ESTIMATES & TREND ANALYSIS**

- 10.1. Regional Market Share Analysis, 2023 & 2030
- 10.2. Regional Market Dashboard
- 10.3. Global Regional Market Snapshot
- 10.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
- 10.5. North America
  - 10.5.1. U.S.
    - 10.5.1.1. Key country dynamics
    - 10.5.1.2. Regulatory framework/Reimbursement
    - 10.5.1.3. Competitive scenario
    - 10.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  - 10.5.2. Canada
    - 10.5.2.1. Key country dynamics
    - 10.5.2.2. Regulatory framework/Reimbursement

- 10.5.2.3. Competitive scenario
- 10.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
- 10.5.3. Mexico
  - 10.5.3.1. Key country dynamics
  - 10.5.3.2. Regulatory framework/Reimbursement
  - 10.5.3.3. Competitive scenario
  - 10.5.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
- 10.6. Europe
  - 10.6.1. UK
    - 10.6.1.1. Key country dynamics
    - 10.6.1.2. Regulatory framework/Reimbursement
    - 10.6.1.3. Competitive scenario
    - 10.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  - 10.6.2. Germany
    - 10.6.2.1. Key country dynamics
    - 10.6.2.2. Regulatory framework/Reimbursement
    - 10.6.2.3. Competitive scenario
    - 10.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  - 10.6.3. France
    - 10.6.3.1. Key country dynamics
    - 10.6.3.2. Regulatory framework/Reimbursement
    - 10.6.3.3. Competitive scenario
    - 10.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  - 10.6.4. Italy
    - 10.6.4.1. Key country dynamics
    - 10.6.4.2. Regulatory framework/Reimbursement
    - 10.6.4.3. Competitive scenario
    - 10.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  - 10.6.5. Spain
    - 10.6.5.1. Key country dynamics
    - 10.6.5.2. Regulatory framework/Reimbursement
    - 10.6.5.3. Competitive scenario
    - 10.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  - 10.6.6. Norway
    - 10.6.6.1. Key country dynamics
    - 10.6.6.2. Regulatory framework/Reimbursement
    - 10.6.6.3. Competitive scenario
    - 10.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  - 10.6.7. Sweden

- 10.6.7.1. Key country dynamics
- 10.6.7.2. Regulatory framework/Reimbursement
- 10.6.7.3. Competitive scenario
- 10.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
- 10.6.8. Denmark
  - 10.6.8.1. Key country dynamics
  - 10.6.8.2. Regulatory framework/Reimbursement
  - 10.6.8.3. Competitive scenario
  - 10.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
- 10.7. Asia Pacific
  - 10.7.1. Japan
    - 10.7.1.1. Key country dynamics
    - 10.7.1.2. Regulatory framework/Reimbursement
    - 10.7.1.3. Competitive scenario
    - 10.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  - 10.7.2. China
    - 10.7.2.1. Key country dynamics
    - 10.7.2.2. Regulatory framework/Reimbursement
    - 10.7.2.3. Competitive scenario
    - 10.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  - 10.7.3. India
    - 10.7.3.1. Key country dynamics
    - 10.7.3.2. Regulatory framework/Reimbursement
    - 10.7.3.3. Competitive scenario
    - 10.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  - 10.7.4. Australia
    - 10.7.4.1. Key country dynamics
    - 10.7.4.2. Regulatory framework/Reimbursement
    - 10.7.4.3. Competitive scenario
    - 10.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  - 10.7.5. South Korea
    - 10.7.5.1. Key country dynamics
    - 10.7.5.2. Regulatory framework/Reimbursement
    - 10.7.5.3. Competitive scenario
    - 10.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  - 10.7.6. Thailand
    - 10.7.6.1. Key country dynamics
    - 10.7.6.2. Regulatory framework/Reimbursement
    - 10.7.6.3. Competitive scenario

10.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)

## 10.8. Latin America

### 10.8.1. Brazil

10.8.1.1. Key country dynamics

10.8.1.2. Regulatory framework/Reimbursement

10.8.1.3. Competitive scenario

10.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)

### 10.8.2. Argentina

10.8.2.1. Key country dynamics

10.8.2.2. Regulatory framework/Reimbursement

10.8.2.3. Competitive scenario

10.8.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)

## 10.9. MEA

### 10.9.1. South Africa

10.9.1.1. Key country dynamics

10.9.1.2. Regulatory framework/Reimbursement

10.9.1.3. Competitive scenario

10.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)

### 10.9.2. Saudi Arabia

10.9.2.1. Key country dynamics

10.9.2.2. Regulatory framework/Reimbursement

10.9.2.3. Competitive scenario

10.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)

### 10.9.3. UAE

10.9.3.1. Key country dynamics

10.9.3.2. Regulatory framework/Reimbursement

10.9.3.3. Competitive scenario

10.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)

### 10.9.4. Kuwait

10.9.4.1. Key country dynamics

10.9.4.2. Regulatory framework

10.9.4.3. Competitive scenario

10.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

## **CHAPTER 11. COMPETITIVE LANDSCAPE**

11.1. Recent Developments & Impact Analysis, By Key Market Participants

11.2. Company/Competition Categorization

11.3. Vendor Landscape

- 11.3.1. List of key distributors and channel partners
- 11.3.2. Key customers
- 11.3.3. Key company market share analysis, 2023
- 11.3.4. Alcon
  - 11.3.4.1. Company overview
  - 11.3.4.2. Financial performance
  - 11.3.4.3. Services benchmarking
  - 11.3.4.4. Strategic initiatives
- 11.3.5. Novartis AG
  - 11.3.5.1. Company overview
  - 11.3.5.2. Financial performance
  - 11.3.5.3. Services benchmarking
  - 11.3.5.4. Strategic initiatives
- 11.3.6. Bausch Health Companies, Inc.
  - 11.3.6.1. Company overview
  - 11.3.6.2. Financial performance
  - 11.3.6.3. Services benchmarking
  - 11.3.6.4. Strategic initiatives
- 11.3.7. Merck & Co., Inc.
  - 11.3.7.1. Company overview
  - 11.3.7.2. Financial performance
  - 11.3.7.3. Services benchmarking
  - 11.3.7.4. Strategic initiatives
- 11.3.8. Regeneron Pharmaceuticals, Inc.
  - 11.3.8.1. Company overview
  - 11.3.8.2. Financial performance
  - 11.3.8.3. Services benchmarking
  - 11.3.8.4. Strategic initiatives
- 11.3.9. Coherus BioSciences, Inc.
  - 11.3.9.1. Company overview
  - 11.3.9.2. Financial performance
  - 11.3.9.3. Services benchmarking
  - 11.3.9.4. Strategic initiatives
- 11.3.10. AbbVie, Inc. (Allergan)
  - 11.3.10.1. Company overview
  - 11.3.10.2. Financial performance
  - 11.3.10.3. Services benchmarking
  - 11.3.10.4. Strategic initiatives
- 11.3.11. Pfizer, Inc.

- 11.3.11.1. Company overview
- 11.3.11.2. Financial performance
- 11.3.11.3. Services benchmarking
- 11.3.11.4. Strategic initiatives
- 11.3.12. Bayer AG
  - 11.3.12.1. Company overview
  - 11.3.12.2. Financial performance
  - 11.3.12.3. Services benchmarking
  - 11.3.12.4. Strategic initiatives
- 11.3.13. Santen Pharmaceutical Co., Ltd.
  - 11.3.13.1. Company overview
  - 11.3.13.2. Financial performance
  - 11.3.13.3. Services benchmarking
  - 11.3.13.4. Strategic initiatives
- 11.3.14. Roche (Genentech, Inc.)
  - 11.3.14.1. Company overview
  - 11.3.14.2. Financial performance
  - 11.3.14.3. Services benchmarking
  - 11.3.14.4. Strategic initiatives
- 11.3.15. Nicox
  - 11.3.15.1. Company overview
  - 11.3.15.2. Financial performance
  - 11.3.15.3. Services benchmarking
  - 11.3.15.4. Strategic initiatives



## I would like to order

Product name: Ophthalmic Drugs Market Size, Share & Trends Analysis Report By Drug Class (Steroidal drugs, Anti-VEGF Agents), By Disease, By Dosage Form, By Route of Administration, By Product Type, By Drug Type, By Region, And Segment Forecasts, 2025 - 2030

Product link: <https://marketpublishers.com/r/O5F00C3269BEN.html>

Price: US\$ 5,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/O5F00C3269BEN.html>